MorphoSys Announces Clinical Milestone In Cancer Program With Bayer Schering Pharma

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Bayer Schering Pharma AG, Germany has filed all necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived antibody-drug conjugate (ADC) in the therapeutic area of oncology. This achievement marks a significant milestone within the Bayer Schering Pharma alliance and triggers a payment to MorphoSys.